Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C7R-EBVSTs for EBV-Positive Lymphoma
NCT04664179Phase 1Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Oct 2022
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of C7R-Epstein-Barr virus-specific T cells in Hodgkin lymphoma (HL), Epstein-Barr virus-positive diffuse large B-cell lymphoma and Epstein-Barr virus-associated T-cell and natural killer-cell lymphoproliferative disease (EBV-T/NK-LPD) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Oct 2022; status: recruiting.
02
Drugs
C7R-Epstein-Barr virus-specific T cells
03
Conditions
Hodgkin lymphoma (HL)Epstein-Barr virus-positive diffuse large B-cell lymphomaEpstein-Barr virus-associated T-cell and natural killer-cell lymphoproliferative disease (EBV-T/NK-LPD)
Beyond the preview
Go deeper on NCT04664179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04664179.